Business Wire

4P-PHARMA

29.4.2024 06:41:26 CEST | Business Wire | Press release

Share
4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.

Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."

This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.

This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.

Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."

About 4P-Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 20268.9.2026 12:30:00 CEST | Press release

Compass will debut Change the Tune in TRD, a new U.S. healthcare provider (HCP) education campaign for treatment-resistant depression (TRD) at Booth #901Seven poster presentations include new health economics and outcomes research (HEOR) data alongside encore analyses from the COMP360 clinical development program Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical development program. Change the Tune in TRD: Advancing HCP Education Change the Tune in TRD is a new educational initiative for U.S. HCPs exploring the neurobiology and navigating care pathways in TRD.

HTEC and Modular Extend MAX and Mojo to Google TPU, Cutting AI Hardware Enablement from Years to Months8.9.2026 12:17:00 CEST | Press release

Advanced compiler and runtime engineering validates a faster, reusable path for bringing AI workloads to new silicon without rebuilding the software stack HTEC, a global AI-first engineering and technology services company, and Modular have demonstrated Modular's AI software stack running on Google's TPU architecture. Presented at ModCon 2026, the work shows that support for a new silicon target can be delivered by extending an existing software foundation rather than rebuilding it for each accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908670401/en/ HTEC, a global AI-first engineering and technology services company, and Modular have demonstrated Modular's AI software stack running on Google's TPU architecture. Presented at ModCon 2026, the work shows that support for a new silicon target can be delivered by extending an existing software foundation rather than rebuilding it for each accelerator. The project

Circle Expands Global Payments Infrastructure with Agreement to Acquire Singapore-Based Cross-Border Payments Platform, Tazapay8.9.2026 12:05:00 CEST | Press release

Proposed acquisition will bring 60+ banking and fintech partners, 100+ payout markets into the Circle ecosystem, accelerating USDC distribution at scale Circle Internet Group, Inc. (NYSE: CRCL), the global financial technology firm and issuer of USDC today announced it has signed a definitive agreement to acquire Tazapay, a Singapore-headquartered B2B cross-border payments infrastructure company focused on serving payment service providers and financial institutions. The deal is expected to close in 2027, subject to customary closing conditions and receipt of regulatory approvals, including approval from the Monetary Authority of Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908409825/en/ “Stablecoin settlement is becoming core infrastructure in the global economy, and combining USDC with Tazapay’s world-class banking relationships, local payout rails, and institutional customer base will accelerate worldwide

Every Entrepreneur Needs Someone to Call: Lenovo and Eva Longoria Open a New Line of Support for Entrepreneurs with “Call Eva”8.9.2026 12:00:00 CEST | Press release

The latest Backing Every Business activation gives entrepreneurs a new way to seek advice, share challenges and bring their biggest business questions directly to fellow business owner, Eva Longoria. Lenovo today announced Call Eva, a new initiative from Lenovo’s global Backing Every Business program that gives entrepreneurs a direct line to call Eva Longoria, Lenovo’s global ambassador, for insights on business growth, leadership and entrepreneurship. Entrepreneurs can now call and leave a voice note with their biggest business questions. Select callers may then be contacted and offered the opportunity to speak with Eva, live on September 16. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908095710/en/ Running a business can feel lonely. The decisions are constant, the challenges are personal and, too often, entrepreneurs are left asking the same question: Who can I call who actually understands what I’m going through? T

57% of Brands Can't Prove ROI on Sports Fan Engagement Despite Rising Investment8.9.2026 11:30:00 CEST | Press release

Infobip’s new global research reveals a gap between higher spend and measurable ROI Research commissioned by Infobip, the global AI-first cloud communications platform celebrating 20 years, shows brands are significantly increasing investment in sports fan engagement even as many struggle to prove business impact. The global study of 500 marketing and digital leaders across industries, including retail, financial services, telecoms, travel, and food & beverage in 11 markets found that brands currently allocate an average of 13% of annual marketing budgets to sports-related activations, and nearly 73% expect investment to increase over the next 12 months. Yet while live sports moments generate the highest levels of fan engagement, nearly half (47%) of organizations admit they struggle to deliver real-time engagement during live events, and more than half (57%) say it is difficult to prove the ROI of their sports marketing investments. Ben Lewis, VP Marketing and Growth at Infobip, said:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye